Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
Our Vision:
Delivering on our Promise
Develop and commercialize medicines with significant potential to improve cancer care
Leadership
Experience and passion to build a company focused on improving the lives of patients
Commitment
We are in this business because we believe we can make a difference. Read about our commitment to improving the lives of cancer patients and their loved ones.